Thoracic retransplantation: Does time to retransplantation matter?


Journal

The Journal of thoracic and cardiovascular surgery
ISSN: 1097-685X
Titre abrégé: J Thorac Cardiovasc Surg
Pays: United States
ID NLM: 0376343

Informations de publication

Date de publication:
12 2023
Historique:
received: 28 02 2022
revised: 18 04 2022
accepted: 03 05 2022
medline: 14 11 2023
pubmed: 2 9 2022
entrez: 1 9 2022
Statut: ppublish

Résumé

For some individuals, chronic allograft failure is best treated with retransplantation. We sought to determine if time to retransplantation impacts short- and long-term outcomes for heart or lung retransplant recipients with a time to retransplantation more than 1 year. The United Network for Organ Sharing/Organ Procurement and Transplantation Network STAR file was queried for all adult, first-time heart (June 1, 2006, to September 30, 2020) and lung (May 1, 2005, to September 30, 2020) retransplantations with a time to retransplantation of at least 1 year. Patients were grouped according to the tertile of time to retransplantation (tertile 1: 1-7.7 years, tertile 2: 7.7-14.7 years, tertile 3: 14.7+ years; lung: tertile 1: 1-2.8 years, tertile 2: 2.8-5.6 years, tertile 3: 5.6+ years). The primary outcome was survival after retransplantation. Comparative statistics identified differences in groups, and Kaplan-Meier methods and a Cox proportional hazard model were used for survival analysis. After selection, 908 heart and 871 lung retransplants were identified. Among heart retransplant recipients, tertile 1 was associated with male sex, smoking history, higher listing status, and increased mechanical support pretransplant. Tertile 3 had the highest rate of concomitant kidney transplant; however, the incidence of morbidity and in-hospital mortality was similar among the groups. Unadjusted and adjusted analyses revealed no survival difference among all groups. Regarding lung retransplant recipients, tertile 1 was associated with increased lung allocation score, pretransplant hospitalization, and mechanical support. Unadjusted and adjusted survival analyses revealed decreased survival in tertile 1. Time to retransplant does not appear to affect heart recipients with a time to retransplantation of more than 1 year; however, shorter time to retransplantation for prior lung recipients is associated with decreased survival. Potential lung retransplant candidates with a time to retransplantation of less than 2.8 years should be carefully evaluated before retransplantation.

Identifiants

pubmed: 36049964
pii: S0022-5223(22)00527-X
doi: 10.1016/j.jtcvs.2022.05.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1529-1541.e4

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL143000
Pays : United States

Informations de copyright

Copyright © 2022 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Asvin M Ganapathi (AM)

Division of Cardiac Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio. Electronic address: Asvin.Ganapathi@osumc.edu.

Victor Heh (V)

Biostatistics, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Justin P Rosenheck (JP)

Division of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Brian C Keller (BC)

Division of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Nahush A Mokadam (NA)

Division of Cardiac Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Brent C Lampert (BC)

Division of Cardiology, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Bryan A Whitson (BA)

Division of Cardiac Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Matthew C Henn (MC)

Division of Cardiac Surgery, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH